Clinical trial
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
NCT05068232
Study timeline
Study start (actual)2022-08-19Date precision: day
Registry last updated2026-03-04
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Small-cell Lung Cancerunresolved
Extensive-stage Small-cell Lung Cancerunresolved
Lung Cancerunresolved
Interventions
Ablative RadiationRADIATION
DurvalumabDRUG · verified · RxNorm: durvalumab
EtoposideDRUG · verified · RxNorm: etoposide
CarboplatinDRUG · verified · RxNorm: carboplatin
Sponsors & collaborators
University of Chicagolead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05068232 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.